Skip to content

To study the mechanism and clinical application of Xuanfudaizhu decoction in treating reflux esophagitis based on TLR4/NF-kB pathway regulating T lymphocyte immune imbalance

To investigate the clinical study of Xuanfudaizhe decoction and Weijiangyi in the treatment of gastroesophageal reflux disease from T lymphocyte immune balance

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077523
Enrollment
Unknown
Registered
2023-11-10
Start date
2023-11-15
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux disease

Interventions

treatment group:Xuanfu Daizhe Decoction was provided by the Pharmacy of Traditional Chinese Medicine of Kunshan Hospital of Traditional Chinese Medicine, and the dosage was referred to the original fo
control group:Omeprazole enteric-soluble capsule (Shandong Luoxin Pharmaceutical), 20mg, once a day, swallow in the morning

Sponsors

Kunshan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the Western diagnostic criteria for gastroesophageal reflux disease; (2) Meet the diagnostic criteria of deficiency qi reverse syndrome in traditional Chinese medicine; (3) Aged between 18 and 70; (4) The patient gives informed consent and is willing to accept appropriate treatment.

Exclusion criteria

Exclusion criteria: (1) Patients with active peptic ulcer, gastrointestinal bleeding, severe dysplasia of gastric mucosa or suspected malignant transformation, and patients with cardiac achardia or postoperative cardiac achardia; (2) There are other organic diseases of the digestive system (such as acute and chronic pancreatitis, cirrhosis, etc.), or systemic diseases that affect the digestive tract dynamics, such as hyperthyroidism, diabetes for more than 10 years, chronic renal insufficiency, mental (anxiety and depression self-rating scale score as severe anxiety or depression) and nervous system diseases; (3) Patients with serious diseases of major organs such as heart, liver and kidney (such as aminotransferase increase of more than 2 times the normal value), hematopoietic system diseases, immune system diseases and tumors; (4) Pregnant and lactating women; (5) Have a history of nervous system and mental illness; (6) Have a history of allergy to the drugs used; (7) Participants who are participating in or within 4 weeks of another clinical trial.

Design outcomes

Primary

MeasureTime frame
gastroscope;GERDQ;In traditional Chinese medicine deficiency qi inverse syndrome type symptom integral;Peripheral blood T cell subsets were detected;

Countries

China

Contacts

Public ContactJu Liu

Kunshan Hospital of Traditional Chinese Medicine

liujupopo@126.com+86 151 5033 9844

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026